| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.31 | 2e-07 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.27 | 2e-07 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.28 | 2e-06 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.23 | 5e-06 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.23 | 0.0002 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.19 | 0.0004 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.19 | 0.0004 |
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0004 |
| mRNA | Bosutinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | 0.5 | 0.002 |